AI-Engineered “GPS” System Guides Immune Cells to Target Cancer

Scientists have developed an artificial intelligence-powered “GPS” navigation system to help immune cells precisely locate and attack cancer cells. This system uses custom-designed miniature proteins to guide the immune response and was recently published in the journal Science.

Researchers at the Technical University of Denmark say the technology is currently in the proof-of-concept stage, with the goal of developing clinically applicable and potentially personalized cancer therapies. Experts at the Fred Hutchinson Cancer Center in the U.S. believe that AI-designed synthetic proteins could extend far beyond oncology, offering novel treatments for a range of diseases.

The team had previously used AI to enhance antivenom proteins for snakebites and is now applying similar techniques to cancer. By genetically engineering T cells to express AI-designed navigation proteins on their surfaces, the researchers improved the cells' ability to recognize and destroy cancer cells—an approach inspired by existing immunotherapies such as CAR-T cell therapy.

The development process involved three coordinated AI tools. The first, a generative model called “RFdiffusion,” designed protein structures tailored to specific cancer targets. A second model generated amino acid sequences capable of folding into those structures. Finally, researchers screened tens of thousands of candidates and selected 44 for testing. One protein successfully directed T cells to effectively kill melanoma cells in lab experiments.

This technology builds on advances in computational protein design, which earned the 2024 Nobel Prize in Chemistry. Compared to traditional methods, AI reduces design timelines from months to days and avoids the inefficiencies of conventional T cell receptor screening.

While the results are promising, the researchers stress that extensive lab and animal testing is still needed before clinical application. Nonetheless, the technology represents a powerful new tool in the fight against cancer and could pave the way for next-generation therapies.